ProfileGDS5678 / 1431807_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 60% 60% 60% 58% 63% 60% 60% 59% 59% 64% 60% 61% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6386660
GSM967853U87-EV human glioblastoma xenograft - Control 23.5869260
GSM967854U87-EV human glioblastoma xenograft - Control 33.5919260
GSM967855U87-EV human glioblastoma xenograft - Control 43.5367160
GSM967856U87-EV human glioblastoma xenograft - Control 53.4735258
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8161363
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7031460
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5797360
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5527859
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5454559
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8596464
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5531560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6513761
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5787260